Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.


Dates: 2004-2017
Funding: Medical Research Council
Collaborators: Department of Cardiothoracic Surgery, John Radcliffe Hospital, Oxford;
Royal Brompton Hospital, London
Information: Oliver Rivero-Arias Helen Campbell

Worldwide, around 800,000 coronary artery bypass grafts are performed annually, and in the UK, the National Service Framework (NSF) aims to increase numbers from 500 to 750 per million of population.

ART is a large multinational randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularisation. The main outcome measure in the trial is death from any cause (cardiovascular and non-cardiovascular mortality). 3102 patients had been recruited by December 2007 in 19 centres in Europe and Australia.  They will be followed for 10 years.

In line with the main outcome of the trial, the primary economic outcome measure in the cost-effectiveness analysis will be life years gained. These will be estimated over the patients' lifetimes, by taking the sum of life years obtained in each arm of the trial within the follow-up period and modelling subsequent life expectancy, using different assumptions about any within-trial treatment effects continuing. A cost per quality adjusted life year will be calculated in the same way, using results from the EQ-5D annual questionnaires. The costing exercise will report information on the surgical procedure resource use and subsequent follow-up costs. The multinational nature of the dataset will be considered when presenting the results of the trial.